The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Evaluation of Votrient in Angiosarcoma
Official Title: Single-arm, Multicenter, Open Label Phase II Trial to Evaluate the Efficacy of Pazopanib in Combination With Paclitaxel in Advanced and Relapsed Angiosarcoma
Study ID: NCT02212015
Brief Summary: Open-label phase II trial investigating the efficacy and safety of the investigational combination of pazopanib and paclitaxel.
Detailed Description: Open-label phase II trial investigating the efficacy and safety of the investigational combination of pazopanib and paclitaxel.This multi-center, open-label, prospective, single arm phase II study was designed to evaluate the clinical efficacy and safety of the experimental combination of pazopanib with paclitaxel in the treatment of patients with advanced or metastatic angiosarcoma.The safety evaluations (physical examination, laboratory checks as defined in protocol, toxicity/adverse event assessment according Eastern Cooperative Oncology Group version 4.0) are scheduled every cycle at day 1, 8, 15 and 29 (= day 1 of the next cycle).
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Universitätsklinik Graz, Graz, , Austria
Universitätsklinik Wien, Wien, , Austria
Helios-Klinikum Bad Saarow, Bad Saarow, , Germany
Helios Klinikum Berlin-Buch, Berlin, , Germany
Universitätsklinikum Carl Gustav Carus, Dresden, , Germany
Universitätsklinikum Essen, Essen, , Germany
Universitätsklinikum Hamburg-Eppendorf, Hamburg, , Germany
Medizinische Hochschule Hannover, Hannover, , Germany
University Medical Center, Mannheim, , Germany
Klinikum der Universität München Campus Großhadern, München, , Germany
Name: Peter Hohenberger, MD
Affiliation: Universitätsmedizin Mannheim / Heidelberg University
Role: PRINCIPAL_INVESTIGATOR